Transcatheter Valve Thrombosis: Predictors, Incidence, and Events

Transcatheter Valve ThrombosisThis study sought to clarify the incidence and predictors of hypoattenuated leaflet thickening (assumed as leaflet thrombosis) imaging in transcatheter bioprosthesis.

 

This study involved 70 consecutive patients who underwent transcatheter aortic valve replacement with the Edwards SAPIEN-XT device and were subjected to follow-up at 6 months and 1 year through multislice computed tomography (CT), echocardiographic data, and laboratory findings.

 

As regards the whole cohort, CT scans revealed hypoattenuated thickening in 1 patient (1.4%) at discharge, 7 (10.0%) at 6 months, and 10 (14.3%) at 1 year after the procedure.

 

The degree of leaflet immobility was well-correlated with the hypoattenuated thickening area as measured through a CT scan (r = 0.68).

 

Thickening was associated with male sex (70% vs. 25%; p = 0.008) and larger sinus of Valsalva (31.0 ± 2.0 mm vs. 28.6 ± 2.6 mm; p = 0.005).

 

Thickening was found in 3 of 49 patients with a 23-mm valve and in 7 of 21 patients with a 26-mm valve (6.1% vs. 33.3%; p = 0,006).

 

As expected, D-dimer levels were significantly increased in the group whose CT scans showed thickening, both at 6 months (2.3 mg/mL vs. 1.1 mg/mL; p = 0.002) and at 1 year (2.7 mg/mL vs. 1.2 mg/mL; p = 0.006). These differences in D-dimer levels were not present at discharge.

 

After obtaining these scans, additional action, such as anticoagulation therapy, was not taken. Despite all of the above, events such as all-cause death or stroke were similar between groups.

 

Conclusion

Hypoattenuated leaflet thickening is relatively frequent but usually subclinical. Gradients through valve and clinical events were not significantly modified, even without active action such as anticoagulant therapy.

 

Male sex, bioprosthesis size, sinus size, and D-dimer levels were associated with this phenomenon.

 

Editorial

This study coincided with the work of a research group led by Nicolaj C. Hansson in points such as low frequency of clinical expression and the association between this phenomenon and larger valves. In the study by Dr. Nicolaj C. Hansson, treatment with warfarin effectively reverted valve thrombosis in 85% of patients, as shown by follow-up transesophageal echocardiography and multislice computed tomography.

 

However, upon evidence of few clinical consequences derived from this phenomenon, and assuming that most patients undergoing transcatheter aortic valve replacement are elderly and present a high risk of bleeding, the decision to apply anticoagulant therapy must be taken while exercising extreme caution.

 

Original title: Incidence, Predictors, and Mid-Term Outcomes of Possible Leaflet Thrombosis After TAVR.

Reference: Ryo Yanagisawa et al. JACC Cardiovasc Imaging. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...